Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT2025-35: Treosulfan, Fludarabine, and PTCy for Allogeneic HSCT
NCT07493538Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2026
- Primary completion
- Mar 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute leukemia, sponsored by Masonic Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute leukemia
Beyond the preview
Go deeper on NCT07493538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493538.